top of page
Home / Information / Ceritinib
Ceritinib
Ceritinib was the first of the 2nd generation TKI's developed by Novartis. The recommended dose is 750mg taken daily.
Be empowered with ALK+ lung cancer information you can rely on
ALK Positive UK is committed to producing reliable, accurate and up to date content reflecting the best available research evidence, and best clinical practice. We aim to provide unbiased information free from any commercial conflicts of interest.
Documents
Name
Summary of Contents
Action
NICE Approves Ceritinib
This document explains Ceritinib for untreated ALK+ NSCLC after crizotinib
bottom of page